Market Place
Sourcing Support
All News #Library
Rare Diseases
MDA 2026 Spotlights Brogidirsen`s 4.5-Year DMD Data
09 Mar 2026 //
PR NEWSWIRE
Brogidirsen 3.5Y Trial Shows Results in Duchenne MD at WMS 2025
14 Oct 2025 //
PR NEWSWIRE
FDA Grants Orphan Drug Status to NS-051/NCNP-04 for DMD
19 Sep 2025 //
PR NEWSWIRE
FDA Fast Tracks NS-229 for Eosinophilic Granulomatosis Treatment
09 Sep 2025 //
PR NEWSWIRE
NS Pharma, Boston Children`s Hospital Ally for Rare Diseases
01 Jul 2025 //
PR NEWSWIRE
FDA Accepts License Application for MPS II Treatment
14 May 2025 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation to NS-229
21 Apr 2025 //
PR NEWSWIRE
NS-050/NCNP-03 Gets FDA Rare Pediatric Disease Designation
10 Sep 2024 //
PR NEWSWIRE
NS Pharma Names New President For Orphan Drug Development
10 Jul 2024 //
PR NEWSWIRE
Japan`s NS Pharma & UK-based MiNA Therapeutics lay focus on rare diseases
04 Apr 2024 //
BIOSPECTRUM ASIA
The European Commission Grants Orphan Drug Designation to NS-229
22 Jan 2024 //
PR NEWSWIRE
NS-018, Treatment for Myelofibrosis, Receives Orphan Drug Designation
08 Aug 2023 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation to NS-089/NCNP-02
07 Aug 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.